Decision Resources, Inc., announces the publication of TNF-Alpha Inhibitors, a new study that reviews the commercial potential of novel agents in this field over a ten-year (2000-2010) forecast period.

(Photo: )

The rationale for using TNF-alpha inhibitors therapeutically has been validated by the dramatic clinical and commercial success of etanercept (Immunex/Wyeth-Ayerst's Enbrel) and infliximab (Centocor/Johnson & Johnson's Remicade) in the rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) markets. In 2000, these two marketed TNF inhibitors accounted for more than $1 billion in major-market sales. By 2010, we expect that the number of treated patients in each disease will more than triple and that sales of TNF inhibitors will achieve a staggering $4 billion for the RA and IBD indications alone. Furthermore, there are a number of disease populations with significant unmet need that may benefit from anti-TNF therapies in the future, particularly psoriasis and psoriatic arthritis (PsA).

New therapies directed against TNF are being developed and evaluated in clinical trials, with expectations of achieving great therapeutic and commercial success. Several notable drugs will be competing with etanercept and infliximab for a share of the market:

  -- Knoll/Abbott's D2E7 (adalimumab) is the first fully human monoclonal      antibody directed against TNF-alpha. D2E7 is widely considered to be      among the most promising new TNF inhibitors in development, and its      commercial potential played a key role in Abbott's recent decision to      acquire Knoll.   -- Celltech/Pharmacia's CDP-870 is an anti-TNF antibody fragment developed      by Celltech as a follow-up to CDP-571, the company's first TNF      inhibitor, and can be manufactured at an exceptionally low cost. In      March 2001, Celltech entered a strategic partnership with Pharmacia to      market CDP-870.  

TNF-Alpha Inhibitors offers invaluable market intelligence for developers of anti-TNF agents. This study is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at

Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2525 (fax), or

In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,

Pharmacia and Alza Face Competition in the Urinary Incontinence Drug Market, According to a Decision Resources Study

View Now